Cargando…

Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples

Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevan...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Stéphanie, Fiebig, Uwe, Liu, Yvonne, Tierney, Rob, Dano, Julie, Worbs, Sylvia, Endermann, Tanja, Nevers, Marie-Claire, Volland, Hervé, Sesardic, Dorothea, Dorner, Martin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690110/
https://www.ncbi.nlm.nih.gov/pubmed/26703727
http://dx.doi.org/10.3390/toxins7124860
_version_ 1782406956602884096
author Simon, Stéphanie
Fiebig, Uwe
Liu, Yvonne
Tierney, Rob
Dano, Julie
Worbs, Sylvia
Endermann, Tanja
Nevers, Marie-Claire
Volland, Hervé
Sesardic, Dorothea
Dorner, Martin B.
author_facet Simon, Stéphanie
Fiebig, Uwe
Liu, Yvonne
Tierney, Rob
Dano, Julie
Worbs, Sylvia
Endermann, Tanja
Nevers, Marie-Claire
Volland, Hervé
Sesardic, Dorothea
Dorner, Martin B.
author_sort Simon, Stéphanie
collection PubMed
description Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevant in the context of the Biological Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection, quantification and discrimination capabilities of 23 expert laboratories from the health, food and security areas. Here we describe three immunological strategies that proved to be successful for the detection and quantification of BoNT/A, B, and E considering the restricted sample volume (1 mL) distributed. To analyze the samples qualitatively and quantitatively, the first strategy was based on sensitive immunoenzymatic and immunochromatographic assays for fast qualitative and quantitative analyses. In the second approach, a bead-based suspension array was used for screening followed by conventional ELISA for quantification. In the third approach, an ELISA plate format assay was used for serotype specific immunodetection of BoNT-cleaved substrates, detecting the activity of the light chain, rather than the toxin protein. The results provide guidance for further steps in quality assurance and highlight problems to address in the future.
format Online
Article
Text
id pubmed-4690110
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46901102015-12-30 Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples Simon, Stéphanie Fiebig, Uwe Liu, Yvonne Tierney, Rob Dano, Julie Worbs, Sylvia Endermann, Tanja Nevers, Marie-Claire Volland, Hervé Sesardic, Dorothea Dorner, Martin B. Toxins (Basel) Article Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevant in the context of the Biological Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection, quantification and discrimination capabilities of 23 expert laboratories from the health, food and security areas. Here we describe three immunological strategies that proved to be successful for the detection and quantification of BoNT/A, B, and E considering the restricted sample volume (1 mL) distributed. To analyze the samples qualitatively and quantitatively, the first strategy was based on sensitive immunoenzymatic and immunochromatographic assays for fast qualitative and quantitative analyses. In the second approach, a bead-based suspension array was used for screening followed by conventional ELISA for quantification. In the third approach, an ELISA plate format assay was used for serotype specific immunodetection of BoNT-cleaved substrates, detecting the activity of the light chain, rather than the toxin protein. The results provide guidance for further steps in quality assurance and highlight problems to address in the future. MDPI 2015-11-26 /pmc/articles/PMC4690110/ /pubmed/26703727 http://dx.doi.org/10.3390/toxins7124860 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Simon, Stéphanie
Fiebig, Uwe
Liu, Yvonne
Tierney, Rob
Dano, Julie
Worbs, Sylvia
Endermann, Tanja
Nevers, Marie-Claire
Volland, Hervé
Sesardic, Dorothea
Dorner, Martin B.
Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title_full Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title_fullStr Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title_full_unstemmed Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title_short Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
title_sort recommended immunological strategies to screen for botulinum neurotoxin-containing samples
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690110/
https://www.ncbi.nlm.nih.gov/pubmed/26703727
http://dx.doi.org/10.3390/toxins7124860
work_keys_str_mv AT simonstephanie recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT fiebiguwe recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT liuyvonne recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT tierneyrob recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT danojulie recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT worbssylvia recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT endermanntanja recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT neversmarieclaire recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT vollandherve recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT sesardicdorothea recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples
AT dornermartinb recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples